Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-51771
Oncologist 2023 Sep 07;289:e703-e711. doi: 10.1093/oncolo/oyad060.
Show Gene links Show Anatomy links

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

Vernaci G , Savarino EV , Patuzzi I , Facchin S , Zingone F , Massa D , Faggioni G , Giarratano T , Miglietta F , Griguolo G , Fassan M , Lo Mele M , Gasparini E , Bisagni G , Guarneri V , Dieci MV .


???displayArticle.abstract???
INTRODUCTION: Patients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have a better event-free survival. The role of gut microbiome in early TNBC is underexplored. METHODS: Microbiome was analyzed by 16SrRNA sequencing. RESULTS: Twenty-five patients with TNBC treated with neoadjuvant anthracycline/taxane-based chemotherapy were included. Fifty-six percent achieved a pCR. Fecal samples were collected before (t0), at 1 (t1), and 8 weeks (t2) from chemotherapy. Overall, 68/75 samples (90.7%) were suitable for microbiome analysis. At t0, pCR group showed a significantly higher α-diversity as compared with no-pCR, (P = .049). The PERMANOVA test on β-diversity highlighted a significant difference in terms of BMI (P = 0.039). Among patients with available matched samples at t0 and t1, no significant variation in microbiome composition was reported over time. CONCLUSIONS: Fecal microbiome analysis in early TNBC is feasible and deserves further investigation in order to unravel its complex correlation with immunity and cancer.

???displayArticle.pubmedLink??? 36940301
???displayArticle.link??? Oncologist
???displayArticle.grants??? [+]


References [+] :
An, Anti-Colorectal Cancer Effects of Probiotic-Derived p8 Protein. 2019, Pubmed